Researchers are testing the drug Sapanisertib to see if it can halt the progression of pancreatic NETs (pNETs) which cannot be surgically removed, have not responded to other treatment, and have spread to other parts of the body.
What is Sapanisertib?
Sapanisertib is one of a group of targeted therapy drugs that interferes with tumor progression by inhibiting an enzyme known as mTOR which a tumor cell needs for growth. In fact this is the same technique used in Afinitor (Everolimus), already approved for NETs.
It is also being tested in a number of different advanced cancers, including bladder, kidney, breast, liver, and certain types of lung cancers, among others.
The Clinical Trial
The primary goal of the phase II study is to evaluate how well pNET tumors respond to Sapanisertib. To qualify for this trial patients must have advanced pNET that cannot be surgically removed, and which have not responded to previous treatment with similar drugs. All participants will receive Sapanisertib, and will be checked periodically to see if their tumors are responding to the drug.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided at this link which provides more details about the Sapanisertib pNET trial – click here and check the inclusion and exclusion criteria; and other data. There are 354 study locations across the USA.
Please also note this drug development was part funded by the NET Research Fundation – read more here.
Thanks for reading